PRESS RELEASE
Q2 2026 — Press release
Q2 2026PDF · 12 pages575 KB
PRESS RELEASE
Philip Morris International Reports 2026 Second-Quarter & First Six-Months Results
and Updates 2026 Full-Year Adjusted Diluted EPS Forecast for Currency Only;
Second-Quarter Reported Diluted EPS declined by 7.7% to $1.80;
Adjusted Diluted EPS grew by 15.2% to $2.20; and by 13.6% excluding currency;
STAMFORD, CT, July 22, 2026 – Philip Morris International Inc. (PMI) (NYSE: PM) today announces its 2026
second quarter results.1
"We delivered outstanding results in the second quarter, driving net revenues to over $11 billion for the first
time with excellent growth across all headline metrics," said Jacek Olczak, Group CEO PMI.
"With a robust first half under our belt, including continued momentum and strong results in our smoke-free
business, we are well positioned to deliver on our full-year targets while investing for future growth."
Results Highlights - Second Quarter 2026
Shipments increased by 2.5% in the quarter, driven by a 7.5% increase in smoke-free mainly due to IQOS and
complemented by a resilient combustible segment, notably in markets where SFPs are banned or have a limited
market presence.
Net revenues increased by 10.4% (7.6% organically) to $11.2 billion, with both the smoke-free (up by 11.7%,
9.7% organically) and combustibles (up by 9.5%, 6.1% organically) businesses contributing positively. Our
smoke-free business accounted for approximately 42% of total net revenues (up by 0.5pp vs. Q2 last year) with
PMI smoke-free products (SFP) now available in 109 markets.
Gross profit increased by 11.5% (8.7% organically), expanding gross margins through strong pricing, scale and
SFP mix benefits. Operating income increased by 22.0% (10.7% organically).
Reported diluted EPS of $1.80 was unfavorably impacted by the non-cash impairment of the RBH equity
investment. Adjusted diluted EPS of $2.20 grew by 15.2%, or by 13.6% excluding a 3 cent favorable currency
impact, which was above prior expectations primarily due to transactional effects.
International Smoke-Free Segment
Group performance continued to be driven by the international smoke-free business, with net revenue growth of
14.2% (11.8% organically) fueled by 8.0% volume growth. Gross profit growth of 17.1% (14.6% organically)
reflects the increasing profitability of our portfolio. IQOS remains the primary growth engine, notwithstanding
expected transient headwinds in Japan and Poland.
Heat-not-burn SFP: IQOS continued to lead the growth of the global category, in which PMI holds around
three-quarters volume share. IQOS gained 0.2pp to reach 9.2% of combined cigarette and HTU industry
volumes in markets where present, and grew shipment volumes by 7.6%. HTU adjusted in-market sales (IMS)
volume grew by 5.1%, reflecting broad-based growth notwithstanding the expected pantry de-loading and initial
consumer adjustment following the April 1 excise-driven price increase in Japan, and the impact of the
characterizing flavor ban in Poland. Excluding Japan and Poland, adjusted IMS grew by 10%.
- 1 -
1 Explanation of PMI's use of non-GAAP measures cited in this document and reconciliations to the most directly comparable U.S. GAAP measures can be found
in the “Non-GAAP Measures, Glossary and Explanatory Notes” section of this release, in Exhibit 99.2 to the company's Form 8-K dated July 22, 2026, and here.
-- 1 of 12 --
• In Japan, while PMI HTU adjusted IMS declined by an estimated 3.4%, it grew by 1.0% excluding the
estimated pantry de-loading impact, broadly in-line with our expectations as consumers adjusted following
our excise-driven price increase, which was the largest in the industry. IQOS maintained a strong category
share, exiting the quarter with 68% in June, with SENTIA playing a key role in capturing price sensitive
TEREA consumers.
• In Europe, IQOS HTU adjusted IMS grew by an estimated 5.1% and IQOS HTU adjusted market share
increased by 1.0pp to 11.8%, notwithstanding ongoing disruptions in Ukraine and the impact of the
characterizing flavor ban in Poland. This growth was led by strong performance in many markets, notably
Germany, Romania, Greece and Spain. Adjusted IMS in Italy continued its strong trajectory (up by 10.8%),
underscoring the category's significant potential across the region. Excluding markets where the
characterizing flavor ban became effective in the last year, adjusted IMS volumes grew by around 8%.
• Outside Europe and Japan, adjusted IMS grew by 14.4% and offtake share increased in key cities across
the globe, including Mexico City, Jakarta, Riyadh, Kuala Lumpur and Taipei. We continue to make progress
in unlocking new markets, including Argentina which introduced legislation regulating the commercialization
and sale of the heat-not-burn category in May.
Oral SFP: Robust modern oral volume growth of 14.7% (26.3% excluding the Nordics) to 0.6 billion pouches
was more than offset by continued declines in the legacy snus business in the Nordics, resulting in a total oral
SFP volume decrease of 7.0%. We continue to expand into new geographies, with ZYN now available in 60
markets and strongly growing volumes in key opportunity markets such as Pakistan, Poland and the UK. Our
focus remains on introducing the segment to legal-age smokers with a relevant product portfolio, including a
range of nicotine strengths and adult-appropriate flavors that meet consumer expectations.
E-vapor SFP: We are delivering increasingly profitable growth in VEEV, with quarterly shipments up by 55.1%.
VEEV now holds the clear #1 closed pod position in Europe, with continued strong growth across a range of
markets, notably Germany, Romania and Greece. PMI remains committed to building and commercializing the
brand in a focused, responsible and profitable manner, leveraging its key role as part of our multicategory
portfolio.
International Combustibles Segment
Cigarette volume increased by 1.1%, with growth in markets such as Turkey, Indonesia and Egypt outweighing
declines in other markets. Net revenues grew by 9.8% (6.4% organically) driven by an exceptional quarter of
10.0% pricing, partly offset by geographic mix. Gross profit grew by 11.5% (8.0% organically). Our cigarette
category volume share stood at 25.3% (flat vs. prior year) despite adverse market mix. Marlboro continued to
gain share (up by 0.3pp) matching its record category share of 11.0%.
U.S. Segment
In the U.S., we delivered a significant sequential improvement in both net revenues and adjusted gross profit
compared to a challenging first quarter, with a 0.7% year-on-year net revenue decline (down 0.9% organically)
composed of a broadly stable top-line for ZYN, declines in cigars, and an unfavorable phasing dynamic in
Wellness. ZYN offtake volumes were flat to slightly growing versus the prior year in a growing category, largely
as a result of the uneven competitive landscape. ZYN shipments increased by 1.8% to 2.9 billion pouches,
despite an inventory tailwind in Q2 2025. In June, we expanded the ZYN portfolio with the first shipments of
ZYN ULTRA (9mg and 11mg moist variants at a lower price-per-pouch), as well as additional flavors within the
ZYN dry flagship lineup. These launches are an important step in enhancing the portfolio and optimizing ZYN's
- 2 -
-- 2 of 12 --
price premium, ensuring ZYN can effectively play in the most dynamic growing segments of the category. We
plan to continue expanding the ZYN lineup with the launch of 1.5mg and 8mg dry variants in the third quarter.
To support the newly expanded ZYN portfolio, we intend to accelerate U.S. investments in the second half to
maximize the long-term value of the brand and also prepare for the future launch of IQOS ILUMA. On June 30,
the FDA granted MRTP authorization to 20 variants in the flagship ZYN range, the first and only for a nicotine
pouch product. This serves as another example of the robust science behind our products and their potential to
reduce the harm caused by smoking.
Second-Quarter 2026 Performance Highlights
Shipment Volume
(billion equivalent units)
PMI International
Smoke-Free International
Combustibles U.S.
Q2 vs. PY Q2 vs. PY Q2 vs. PY Q2 vs. PY
Total 205.2 2.5% 44.7 8.0% 156.9 1.1% 3.5 1.8%
Cigarettes 156.9 1.1% 156.9 1.1%
SFP 48.2 7.5% 44.7 8.0% 3.5 1.8%
HTU 41.8 7.6% 41.8 7.6% – 100%
Oral SFP 5.1 (1.2)% 1.6 (7.0)% 3.5 1.8%
E-Vapor 1.3 55.1% 1.3 55.1%
"-" indicates zero volumes or less than 50 million units
PMI International
Smoke-Free International
Combustibles U.S.
Net Revenues ($ bn) $11.2 $3.9 $6.5 $0.9
reported vs. Q2 2025 10.4% 14.2% 9.8% (0.7)%
organic vs. Q2 2025 7.6% 11.8% 6.4% (0.9)%
Gross Profit ($ bn) $7.7 $2.7 $4.4 $0.6
reported vs. Q2 2025 11.5% 17.1% 11.5% (9.2)%
organic vs. Q2 2025 8.7% 14.6% 8.0% (8.9)%
OCI ($ bn) $4.7 $4.6 $0.1
reported vs. Q2 2025 21.9% 25.0% (52.5)%
organic vs. Q2 2025 10.6% 13.2% (19.1)%
Operating Income ($ bn) $4.5
reported vs. Q2 2025 22.0%
organic vs. Q2 2025 10.7%
Note: Sums might not foot to total due to rounding.
2026 2025 Change
Reported Diluted EPS $1.80 $1.95 (7.7)%
Amortization of intangibles 0.13 0.12
Fair value adjustment for equity security investments (0.06) (0.17)
Restructuring charges – 0.13
Income tax impact associated with Swedish Match AB financing 0.01 (0.18)
Impairment related to the RBH equity investment 0.33 –
Egypt sales tax settlement adjustment (0.01) –
Impairment of goodwill – 0.03
Tax items – 0.03
Adjusted Diluted EPS $2.20 $1.91 15.2%
Less: Currency 0.03
Adjusted Diluted EPS, excluding Currency $2.17 $1.91 13.6%
- 3 -
-- 3 of 12 --
First Six Months 2026 Performance Highlights
Shipment Volume
(billion equivalent units)
PMI International
Smoke-Free International
Combustibles U.S.
YTD vs. PY YTD vs. PY YTD vs. PY YTD vs. PY
Total 389.4 0.4% 88.8 9.9% 294.2 (1.9)% 6.3 (10.0)%
Cigarettes 294.2 (1.9)% 294.2 (1.9)%
SFP 95.2 8.3% 88.8 9.9% 6.3 (10.0)%
HTU 83.1 9.4% 83.0 9.4% – +100%
Oral SFP 9.6 (8.8)% 3.2 (6.1)% 6.3 (10.1)%
E-Vapor 2.6 72.0% 2.6 72.0%
"-" indicates zero volumes or less than 50 million units
PMI International
Smoke-Free International
Combustibles U.S.
Net Revenues ($ bn) $21.3 $7.7 $12.1 $1.5
reported vs. YTD 2025 9.8% 19.2% 8.4% (16.1)%
organic vs. YTD 2025 5.3% 13.7% 3.8% (16.5)%
Gross Profit ($ bn) $14.6 $5.4 $8.2 $0.9
reported vs. YTD 2025 10.9% 22.6% 10.7% (27.9)%
organic vs. YTD 2025 6.4% 16.9% 6.1% (27.5)%
OCI ($ bn) $8.7 $8.8 $(0.1)
reported vs. YTD 2025 13.6% 20.4% -(100)%
organic vs. YTD 2025 5.9% 11.7% (50.2)%
Operating Income ($ bn) $8.4
reported vs. YTD 2025 16.1%
organic vs. YTD 2025 6.1%
Note: Sums might not foot to total due to rounding.
2026 2025 Change
Reported Diluted EPS $3.36 $3.67 (8.4)%
Amortization of intangibles 0.25 0.24
Fair value adjustment for equity security investments 0.16 (0.26)
Restructuring charges 0.01 0.13
Income tax impact associated with Swedish Match AB financing 0.06 (0.24)
Impairment related to the RBH equity investment 0.33 –
Egypt sales tax settlement adjustment (0.01) –
Impairment of goodwill – 0.03
Tax items – 0.03
Adjusted Diluted EPS $4.16 $3.60 15.6%
Less: Currency 0.22
Adjusted Diluted EPS, excluding Currency $3.94 $3.60 9.4%
- 4 -
-- 4 of 12 --
Middle East Conflict
The Middle East conflict has had a minor impact on our business so far, mainly impacting transport, energy and
other input costs, as was expected. While we have observed increased energy prices and some disruption in
energy supply in a number of markets, it has not yet resulted in a discernible shift in consumer behavior. The
situation remains volatile, and it is difficult to assess the broader long term implications for the consumer or the
global cost environment. In our full-year forecast we do not assume a prolonged impact, however we have
factored in some increases in transport, energy and other input costs. We will continue to closely monitor
developments to assess the mid-to-long term consequences.
Non-Cash Impairment of RBH Equity Investment
In May 2026, pursuant to its obligation under its court-approved plan of compromise and arrangement ("Plan"),
PMI's deconsolidated Canadian affiliate, RBH, provided an annual business plan to its Plan Administrator
containing updated five-year financial projections reflecting current industry dynamics. As a result, PMI
determined that the estimated fair value of its investment in RBH was lower than its carrying value and
recorded a non-cash impairment charge of $511 million in the second quarter of 2026, representing 33 cents of
diluted EPS. RBH remains deconsolidated from the PMI group, with a remaining carrying value of $51 million
as of June 30.
- 5 -
-- 5 of 12 --
2026 Full-Year Forecast
2026
Forecast 2025 Growth
Reported Diluted EPS $7.19 - $7.34 $ 7.26
Adjustments
Amortization of intangibles 0.50 0.50
Fair value adjustment for equity security investments 0.16 (0.18)
Restructuring charges 0.03 0.14
Income tax impact associated with Swedish Match AB financing 0.06 (0.25)
Impairment related to the RBH equity investment 0.33 —
Egypt sales tax settlement adjustment (0.01) —
Other 2025 adjustments(1) – 0.07
Total Adjustments 1.07 0.28
Adjusted Diluted EPS $8.26 - $8.41 $ 7.54 9.5% - 11.5%
Less: Currency 0.15
Adjusted Diluted EPS, excluding currency $8.11 - $8.26 $ 7.54 7.5% - 9.5%
(1) Includes: $0.10 Germany excise tax classification litigation charge; ($0.10) RBH (Canada) Plan Implementation, including dividend income, net; $0.09
Impairment of Wellness business related equity investment; $0.06 Loss on expected sale of consumer accessories and other businesses; $0.03 Impairment of
goodwill; ($0.11) Tax items
Reported diluted EPS is forecast to be in a range of $7.19 to $7.34, at prevailing exchange rates. Excluding a
total 2026 adjustment of $1.07 per share, this forecast represents a projected increase of 9.5% to 11.5% versus
adjusted diluted EPS of $7.54 in 2025. This includes a favorable currency impact of $0.15, at prevailing
exchange rates (previously $0.20), as versus our previous forecast the benefit of transactional gains in the
second quarter are more than offset by translational effects of the strengthening U.S. dollar. Excluding currency,
this forecast represents a projected increase of 7.5% to 9.5% versus adjusted diluted EPS of $7.54 in 2025, as
outlined in the above table.
2026 Full-Year Forecast Assumptions
• Broadly stable to slightly growing (previously broadly stable) total PMI cigarette and SFP shipment volume,
with high-single digit SFP shipment volume growth, and a cigarette shipment volume decline of 2% to 3%
(previously around 3%);
• Net revenue growth of 5% to 7% on an organic basis;
• Organic operating income growth of 7% to 9%;
• Full-year amortization of acquired intangibles of $0.50 per share;
• Broadly stable net financing costs;
• An effective tax rate, excluding discrete tax events, of around 21.5%;
• Operating cash flow around $13.5 billion at prevailing exchange rates, subject to year-end working capital
requirements;
• Capital expenditures of $1.4 to $1.6 billion, predominantly supporting the smoke-free business;
• Further net debt to adjusted EBITDA ratio improvement as we target a ratio of close to 2.0x by the end of
2026, at prevailing exchange rates;
• No share repurchases; and
• Third quarter adjusted diluted EPS of $2.20 to $2.25, including an estimated unfavorable currency impact of
8 cents at prevailing exchange rates.
Factors described in the Forward-Looking and Cautionary Statements section of this release represent
continuing risks to these projections.
- 6 -
-- 6 of 12 --
Second-Quarter 2026 Operating Review
Net Revenues
(in millions) PMI International
Smoke-Free International
Combustibles U.S.
2025 $10,140 $3,395 $5,883 $862
Price 689 86 588 15
Volume/Mix/Other 81 316 (212) (23)
Acquisitions & Divestitures (17) (17) — —
Currency 299 98 200 1
2026 $11,192 $3,877 $6,459 $856
vs. Q2 2025 10.4% 14.2% 9.8% (0.7)%
Organic growth 7.6% 11.8% 6.4% (0.9)%
2
Gross Profit
(in millions) PMI International
Smoke-Free International
Combustibles U.S.
2025 $6,866 $2,319 $3,936 $611
Price 689 86 588 15
Volume/Mix/Other (43) 198 (217) (24)
Cost (47) 56 (56) (47)
Acquisitions & Divestitures (4) (4) — —
Currency 198 62 137 (1)
2026 $7,659 $2,716 $4,388 $555
vs. Q2 2025 11.5% 17.1% 11.5% (9.2)%
Adjustments* 6 1 — 5
2026 Adjusted Gross Profit $7,665 $2,717 $4,388 $560
vs. Q2 2025 11.5% 17.1% 11.5% (9.0)%
Organic growth 8.7% 14.6% 8.0% (8.9)%
2026 Adj. Gross Profit Margin 68.5% 70.1% 67.9% 65.4%
vs. Q2 2025 0.7pp 1.8pp 1.0pp (6.0)pp
Organic growth 0.7pp 1.7pp 1.0pp (5.8)pp
(*) For a list of adjusting items refer to the “Non-GAAP Measures, Glossary and Explanatory Notes” section of this release, in Exhibit
99.2 to the company's Form 8-K dated July 22, 2026.
PMI
(in millions)
Variance
Favorable / (Unfavorable)
2026 2025 Change Total Price Volume /
Mix /
Other Cost Acq. /
Divest. Currency
Net Revenues 11,192 10,140 10.4% 1,052 689 81 – (17) 299
Cost of Sales(1) (3,533) (3,274) (7.9)% (259) – (124) (47) 13 (101)
Gross Profit 7,659 6,866 11.5% 793 689 (43) (47) (4) 198
Marketing, Administration
and Research Costs(2) (2,981) (2,988) 0.2% 7 – – 114 2 (109)
Impairment of goodwill — (41) +100% 41 – – 41 – –
Corporate Expenses & Other (148) (125) (18.4)% (23) – – (10) – (13)
Operating Income 4,530 3,712 22.0% 818 689 (43) 98 (2) 76
Adjustments* (243) (534) 54.5% 291 – – 291 – –
Adj. Operating Income 4,773 4,246 12.4% 527 689 (43) (193) (2) 76
Adj. OI Margin 42.6 % 41.9 % 0.7pp
(1) Includes $6 million in 2026 and $6 million in 2025 related to the adjusting items shown below Operating Income
(2) Includes $237 million in 2026 and $487 million in 2025 related to the adjusting items shown below Operating Income
(*) For a list of adjusting items refer to the “Non-GAAP Measures, Glossary and Explanatory Notes” section of this release, in Exhibit 99.2 to the company's
Form 8-K dated July 22, 2026.
- 7 -
Note: Sums might not foot to total due to rounding.2
-- 7 of 12 --
Total PMI
• Estimated industry volume (excluding China and the U.S.) for cigarettes and HTUs increased by 0.8%.
• Net revenues increased by 7.6% organically, mainly reflecting: a favorable pricing variance mainly driven
by international combustibles; supported by favorable volume/mix, driven by international smoke-free
volumes, notwithstanding adverse international combustibles mix.
• Operating income increased by 10.7% on an organic basis, largely reflecting the same factors as for net
revenues.
International Smoke-Free Segment
• Shipment volume grew by 8.0%, with broad based growth across markets, notably Taiwan, Romania,
and Greece.
• Net revenues increased by 11.8% on an organic basis, reflecting: a favorable volume/mix driven by
higher HTU and e-vapor volumes and a favorable pricing variance due to HTUs.
• Gross profit increased by 14.6% organically mainly due to the same factors as for net revenues.
International Combustibles Segment
• Shipment volume grew by 1.1% with notable increases in Turkey, Indonesia, and Egypt.
• Net revenues increased by 6.4% on an organic basis, reflecting: a favorable pricing variance, partially
offset by unfavorable mix as growth in developing economies more than offset declines in Europe.
• Gross profit increased by 8.0% organically due to the same factors as for net revenues.
U.S. Segment
• Net revenues slightly decreased by 0.9% organically, primarily reflecting: broadly stable ZYN revenues,
declines in the cigar business, and unfavorable phasing dynamics in Wellness.
• Gross profit decreased by 8.9% on an organic basis reflecting the same factors as for net revenues and
higher manufacturing costs linked to the expansion of our footprint.
• Adjusted OCI decreased by 19.1% organically, to $279 million, reflecting the same factors as for
adjusted gross profit and phasing of investments in marketing, administration and research costs as part
of the Aspeya Wellness business.
- 8 -
-- 8 of 12 --
First Six Months 2026 Operating Review
Net Revenues
(in millions) PMI International
Smoke-Free International
Combustibles U.S.
2025 $19,441 $6,471 $11,209 $1,762
Price 1,150 174 1,042 (65)
Volume/Mix/Other (125) 715 (614) (226)
Acquisitions & Divestitures (17) (17) — —
Currency 889 371 510 8
2026 $21,338 $7,713 $12,147 $1,478
vs. YTD 2025 9.8% 19.2% 8.4% (16.1)%
Organic growth 5.3% 13.7% 3.8% (16.5)%
3
Gross Profit
(in millions) PMI International
Smoke-Free International
Combustibles U.S.
2025 $13,136 $4,405 $7,435 $1,296
Price 1,150 174 1,042 (65)
Volume/Mix/Other (238) 488 (522) (205)
Cost (75) 83 (68) (89)
Acquisitions & Divestitures (4) (4) — —
Currency 595 254 342 (1)
2026 $14,564 $5,400 $8,229 $935
vs. YTD 2025 10.9% 22.6% 10.7% (27.9)%
Adjustments* 12 1 — 10
2026 Adjusted Gross Profit $14,576 $5,402 $8,229 $945
vs. YTD 2025 10.9% 22.6% 10.7% (27.6)%
Organic growth 6.4% 16.9% 6.1% (27.5)%
2026 Adj. Gross Profit Margin 68.3% 70.0% 67.7% 63.9%
vs. YTD 2025 0.7pp 1.9pp 1.4pp (10.2)pp
Organic growth 0.7pp 1.9pp 1.5pp (9.7)pp
(*) For a list of adjusting items refer to the “Non-GAAP Measures, Glossary and Explanatory Notes” section of this release, in Exhibit
99.2 to the company's Form 8-K dated July 22, 2026.
PMI
(in millions)
Variance
Favorable / (Unfavorable)
2026 2025 Change Total Price Volume /
Mix /
Other Cost Acq. /
Divest. Currency
Net Revenues 21,338 19,441 9.8% 1,897 1,150 (125) – (17) 889
Cost of Sales(1) (6,774) (6,305) (7.4)% (469) – (113) (75) 13 (294)
Gross Profit 14,564 13,136 10.9% 1,428 1,150 (238) (75) (4) 595
Marketing, Administration
and Research Costs(2) (5,838) (5,416) (7.8)% (422) – – (116) 2 (308)
Impairment of Goodwill — (41) +100% 41 – – 41 – –
Corporate Expenses & Other (303) (423) 28.4% 120 – – (11) – 131
Operating Income 8,423 7,256 16.1% 1,167 1,150 (238) (161) (2) 418
Adjustments* (518) (780) 33.6% 262 – – 262 – –
Adj. Operating Income 8,941 8,036 11.3% 905 1,150 (238) (423) (2) 418
Adj. OI Margin 41.9 % 41.3 % 0.6pp
(1) Includes $12 million in 2026 and $11 million in 2025 related to the adjusting items shown below Operating Income
(2) Includes $506 million in 2026 and $728 million in 2025 related to the adjusting items shown below Operating Income
(*) For a list of adjusting items refer to the “Non-GAAP Measures, Glossary and Explanatory Notes” section of this release, in Exhibit 99.2 to the company's
Form 8-K dated July 22, 2026.
- 9 -
Note: Sums might not foot to total due to rounding.3
-- 9 of 12 --
Total PMI
• Estimated industry volume (excluding China and the U.S.) for cigarettes and HTUs declined by 0.4%.
• Net revenues increased by 5.3% organically, mainly reflecting: a favorable pricing variance mainly driven
by international combustibles; partly offset by unfavorable volume/mix, mainly driven by lower
international combustibles and U.S. volumes, notwithstanding higher international smoke-free volumes.
• Operating income increased by 6.1% on an organic basis, reflecting the same factors as for net
revenues, partially offset by higher marketing, administration and research costs.
International Smoke-Free Segment
• Shipment volume grew by 9.9%, notably due to Taiwan, Italy, and Global Travel Retail.
• Net revenues increased by 13.7% on an organic basis, reflecting: a favorable volume/mix driven by
higher HTU and e-vapor volumes and a favorable pricing variance due to higher HTU pricing.
• Gross profit increased by 16.9% organically mainly due to the same factors as for net revenues
International Combustibles Segment
• Shipment volume declined by 1.9% with notable decreases in Russia, Mexico, and Germany.
• Net revenues increased by 3.8% on an organic basis, reflecting: an unfavorable volume/mix; more than
offset by a favorable pricing variance.
• Gross profit increased by 6.1% organically due to the same factors as for net revenues.
U.S. Segment
• Net revenues decreased by 16.5% organically, reflecting: unfavorable dynamics in the first quarter with
ZYN volumes impacted by distributor and trade inventory movements and an unfavorable price
comparison due to low levels of ZYN promotional activity in the prior year.
• Gross profit decreased by 27.5% on an organic basis reflecting the same factors as for net revenues
and higher manufacturing costs.
• Adjusted OCI decreased by 50.2% organically, to $379 million, reflecting the same factors as for gross
profit and increased investments in marketing, administration and research costs.
Conference Call
A conference call hosted by Emmanuel Babeau, Group Chief Financial Officer, and Massimo Andolina, incoming
Group Chief Financial Officer, will be webcast at 9:00 a.m., Eastern Time, on July 22, 2026. The webcast can be
accessed here. Further market data will be provided in an appendix to the webcast presentation.
Investor Relations: Media:
InvestorRelations@pmi.com Corey.Henry@pmi.com
Stamford, CT: +1 (203) 905 2413 Stamford, CT: +1 (203) 905 2410
Lausanne: +41 582 424 500
- 10 -
-- 10 of 12 --
Philip Morris International: A Global Smoke-Free Champion
Philip Morris International is a leading international consumer goods company, actively delivering a smoke-free
future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector.
The company’s current product portfolio primarily consists of cigarettes and smoke-free products, including heat-
not-burn, nicotine pouch and e-vapor products. Our smoke-free products are available for sale in 109 markets as
of June 30, 2026. As of December 31, 2025 PMI estimates they were used by over 43 million legal-age
consumers around the world, many of whom have moved away from cigarettes or significantly reduced their
consumption. The smoke-free business accounted for approximately 42% of PMI’s second-quarter 2026 total net
revenues. Since 2008, PMI has invested over $16 billion to develop, scientifically substantiate and
commercialize innovative smoke-free products for adults who would otherwise continue to smoke or use other
nicotine-containing consumer products, with the goal of completely ending the sale of cigarettes. This includes
the building of world-class scientific assessment capabilities, notably in the areas of pre-clinical systems
toxicology, clinical and behavioral research, as well as post-market studies. Following a robust science-based
review, the U.S. Food and Drug Administration has authorized the marketing of Swedish Match’s General snus
and ZYN nicotine pouches and versions of PMI’s IQOS devices and consumables - the first-ever such
authorizations in their respective categories. Versions of IQOS devices and consumables, General snus and 20
ZYN nicotine pouch variants also obtained the first-ever Modified Risk Tobacco Product authorizations from the
FDA. With a strong foundation and significant expertise in life sciences, PMI has a long-term ambition to expand
into wellness areas. References to “PMI”, “we”, “our” and “us” mean Philip Morris International Inc., and its
subsidiaries. For more information, please visit www.pmi.com and www.pmiscience.com.
Forward-Looking and Cautionary Statements
This release contains projections of future results and goals and other forward-looking statements, including
statements regarding expected financial or operational performance; capital allocation plans; investment
strategies; regulatory outcomes; market expectations; business plans and strategies. Achievement of future
results is subject to risks, uncertainties and inaccurate assumptions. In the event that risks or uncertainties
materialize, or underlying assumptions prove inaccurate, actual results could vary materially from those
contained in such forward-looking statements. Pursuant to the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995, PMI is identifying important factors that, individually or in the aggregate, could
cause actual results and outcomes to differ materially from those contained in any forward-looking statements
made by PMI.
PMI's business risks include: marketing and regulatory restrictions that could reduce our competitiveness, disrupt
our SFP commercialization efforts, eliminate our ability to communicate with adult consumers, or ban certain of
our products in certain markets or countries; excise tax increases and discriminatory tax structures; health
concerns relating to the use of tobacco and other nicotine-containing products; litigation related to tobacco and/
or nicotine products and intellectual property rights; intense competition; inability to anticipate changes in adult
consumer preferences; use and reliance on third-parties; the adverse effects of global and individual country
economic, regulatory and political developments, natural disasters and conflicts; geopolitical instability; the
impact and consequences of Russia's invasion of Ukraine; changes in adult smoker behavior; continued decline
of tax-paid cigarettes; lost revenues as a result of counterfeiting, contraband and cross-border purchases;
governmental investigations; unfavorable currency exchange rates and currency devaluations, sustained periods
of elevated inflation, and limitations on the ability to repatriate funds; adverse changes in applicable corporate
tax laws; disruptions in the credit markets or changes to its credit ratings; recent and potential future tariffs
- 11 -
-- 11 of 12 --
imposed by the U.S. and other countries; adverse changes in the cost, availability, and quality of tobacco and
other agricultural products and raw materials, as well as product components for its electronic devices; and the
integrity of its information systems and effectiveness of its data privacy policies. PMI's future profitability may
also be adversely affected should it be unsuccessful, in key markets or systemically, in its efforts to introduce,
commercialize, and grow smoke-free products or if regulation or taxation do not differentiate between such
products and cigarettes; if it is unable to successfully introduce new products, and promote brand equity; if there
are prolonged disruptions of facilities used to produce its products; if it is unable to enter new markets or improve
its margins through increased prices and productivity gains; if other market participants are more successful in
their SFP commercialization efforts; if it is unable to attract and retain the best global talent; or if it is unable to
successfully integrate and realize the expected benefits from recent transactions and acquisitions. Future results
are also subject to the lower predictability of our smoke-free products performance.
PMI is further subject to other risks detailed from time to time in its publicly filed documents, including PMI's
Annual Report on Form 10-K for the fourth quarter and year ended December 31, 2025, and the Quarterly
Report on Form 10-Q for the second quarter ended June 30, 2026, which will be filed in the coming days. PMI
cautions that the foregoing list of important factors is not a complete discussion of all potential risks and
uncertainties. PMI does not undertake to update any forward-looking statement that it may make from time to
time, except in the normal course of its public disclosure obligations.
Non-GAAP Measures, Glossary and Explanatory Notes
Reconciliations of non-GAAP measures in this release to the most directly comparable U.S. GAAP measures
can be found in Exhibit 99.2 to the Form 8-K dated July 22, 2026, and here. A glossary of key terms, definitions
and explanatory notes is available in the aforementioned Exhibit 99.2 and on the same webpage, where
additional financial schedules, as well as adjustments and other calculations have also been made available.
Management reviews net revenues, gross profit, operating companies income, operating income, operating cash
flow and earnings per share, or "EPS," on an adjusted basis, which may exclude the impact of currency and
other items such as acquisitions, divestitures, restructuring costs, tax items and other adjusting items.
Additionally, starting in 2022 and on a comparative basis, for these measures other than net revenues and
operating cash flow, PMI includes adjustments to add back amortization expense on acquisition related
intangible assets that are recorded as part of purchase accounting and contribute to PMI’s revenue generation,
as well as impairment of intangible assets, if any. While amortization expense on acquisition related intangible
assets is excluded in these adjusted measures, the net revenues generated from these acquired intangible
assets are included in the company's adjusted measures, unless otherwise stated. Currency-neutral and organic
growth rates reflect the way management views underlying performance for these measures. PMI believes that
such measures provide useful insight into underlying business trends and results. Management reviews these
measures because they exclude changes in currency exchange rates and other factors that may distort
underlying business trends, thereby improving the comparability of PMI’s business performance between
reporting periods. Furthermore, PMI uses several of these measures in its management compensation program
to promote internal fairness and a disciplined assessment of performance against company targets. PMI
discloses these measures to enable investors to view the business through the eyes of management.
Non-GAAP measures used in this release should neither be considered in isolation nor as a substitute for the
financial measures prepared in accordance with U.S. GAAP.
- 12 -
-- 12 of 12 --